Quarterly ResultMay 6, 2026, 08:37 AM
Taysha Gene Therapies Q1 Net Loss $(42.4M); Revenue $0
AI Summary
Taysha Gene Therapies reported a net loss of $(42.4) million for Q1 2026, a significant increase from $(21.5) million in Q1 2025, with revenue dropping to $0 from $2.3 million. Research and development expenses more than doubled to $33.8 million. The company ended the quarter with $276.6 million in cash and cash equivalents, which it expects to fund operations for at least 12 months. Additionally, the Astellas GAN and Rett options expired in October 2025, returning full rights to the TSHA-102 program to Taysha.
Key Highlights
- Net loss for Q1 2026 was $(42.4) million, up from $(21.5) million in Q1 2025.
- Revenue for Q1 2026 was $0, down from $2.3 million in Q1 2025.
- Research and development expenses increased to $33.8 million from $15.6 million.
- Cash and cash equivalents totaled $276.6 million as of March 31, 2026.
- Accumulated deficit reached $(753.7) million as of March 31, 2026.
- Net cash used in operating activities was $(40.9) million for Q1 2026.
- Astellas GAN and Rett options expired in October 2025; Taysha regained full rights to TSHA-102.
- $50.0 million outstanding on 2025 Trinity Term Loans as of March 31, 2026.
Price Impact
More from TSHA